{"nctId":"NCT00457015","briefTitle":"Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)","startDateStruct":{"date":"2007-04-01","type":"ACTUAL"},"conditions":["Hereditary Angioedema (HAE)"],"count":96,"armGroups":[{"label":"DX-88 (ecallantide)","type":"EXPERIMENTAL","interventionNames":["Drug: ecallantide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Phosphate Buffer Saline (PBS), pH 7.0"]}],"interventions":[{"name":"ecallantide","otherNames":["DX-88"]},{"name":"Phosphate Buffer Saline (PBS), pH 7.0","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 10 years of age or older\n* Executed informed consent\n* Documented diagnosis of HAE (Type I or II)\n* Presentation at the site within 8 hours of patient recognition of an moderate to severe HAE acute attack\n\nExclusion Criteria:\n\n* Receipt of an investigational drug or device, within 30 days prior to study treatment\n* Receipt of non-investigational C1-INH within 7 days of treatment\n* Receipt of DX-88 (ecallantide) within 3 days prior to study treatment\n* Diagnosis of acquired angioedema (AAE), estrogen-dependent angioedema or drug-induced angioedema (including angiotensin-converting enzyme inhibitor induced angioedema)\n* Pregnancy or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose","description":"The Mean Symptom Complex Severity (MSCS) score is a validated, comprehensive point-in-time measure of symptom severity. At baseline and 4 hours, patients rated the severity on a categorical scale (0 = normal, 1 = mild, 2 = moderate, 3 = severe) for symptoms at each affected anatomical location. Ratings were averaged to obtain the MSCS score. A decrease in MSCS score reflected an improvement in symptoms; clinically meaningful improvement was indicated by a reduction in the score of 0.30 or more.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.50"},{"groupId":"OG001","value":"2.0","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.75"},{"groupId":"OG001","value":"1.6","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.63"},{"groupId":"OG001","value":"-0.4","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Treatment Outcome Score at 4 Hours Post-Dose","description":"Treatment Outcome Score (TOS) is a validated, comprehensive measure of symptom response to treatment. At 4 hours , patient assessment of response characterized by their change from baseline in symptom severity and collected by anatomic site of attack involvement, was recorded on a categorical scale (significant improvement \\[100; best value\\]to significant worsening \\[-100; worst value\\]). Clinically meaningful improvement was indicated by a TOS of 30 or higher.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":"49.70"},{"groupId":"OG001","value":"8.1","spread":"63.18"}]}]}]},{"type":"SECONDARY","title":"Patients With Significant Improvement in Overall Response","description":"Patients were to be asked to perform an overall response assessment at intervals during the first 4 hours post-dose. Assessments were to be made relative to baseline (ie, immediately before initial dosing) using a 5-category scale. Categories were: significant improvement = \"a lot better or resolved\"; improvement = \"a little better\"; same = response unchanged; worsening = \"a little worse\"; significant worsening = \"a lot worse\". Significant improvement is the first time that a patient responded to the overall response assessment as \"a lot better or resolved.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With a Successful Response at 4 Hours Post-dosing, Based on the Change From Baseline in the MSCS Score","description":"A successful response was defined as improvement in existing laryngeal symptom complex,stabilization of an existing peripheral symptom complex, or a change from baseline in the MSCS score at 4 hours of at least -1.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Maintaining a Significant Improvement in Overall Response Through 24 Hours","description":"Maintenance of significant improvement was defined as achieving and maintaining a significant improvement in overall response through 24 hours after dosing. Patient response categories were: significant improvement = \"a lot better or resolved\"; improvement = \"a little better\"; same = response unchanged; worsening = \"a little worse\"; significant worsening = \"a lot worse\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Headache","Nausea","Diarrhoea","Vomiting"]}}}